FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2899615648> ?p ?o ?g. }

• W2899615648 abstract "Background The EGFR (epithelial growth factor receptor) ligands amphiregulin (AREG) and epiregulin (EREG) have been considered as predictors for EGFR-antibody efficacy. The effect of AREG and EREG expression levels in primary tumor samples on the outcome of bevacizumab-treated patients is unknown. Patients and Methods Formalin-fixed paraffin-embedded (FFPE) tumor samples from surgically removed primaries of the AIO KRK-0207 trial have been tested for AREG and EREG expression. The AIO KRK-0207 trial was a randomized phase-3 study to investigate the best maintenance strategy after oxaliplatin/fluoropyrimidine plus bevacizumab induction treatment in patients with mCRC. Association of AREG and EREG levels with outcome parameters were investigated, taking into account RAS and BRAF mutations. Results A total of 331 tumor samples had measurable AREG and EREG tissue levels. In the total cohort using continuous expression levels, higher logAREG and logEREG levels were asso-ciated with a significant longer overall survival (OS) (HR 0.80; p= 0.003 and HR 0.78; p= 0.001 respectively). The subgroup of BRAF mutant tumors displayed significantly lower AREG and EREG levels compared to wild-type tumors. The prognostic effect of AREG and EREG expression was limited to the double wild-type subpopulation, whereas in the RAS mutant and BRAF mutant subgroups no prognostic effect was detected. Conclusion Low logAREG and logEREG levels are associated with a shorter OS in oxali-platin/fluoropyrimidine plus bevacizumab treated patients. As low AREG and EREG level are associated with BRAF mutations, the prognostic value of EREG and AREG levels is limited to the RAS and BRAF wild-type subpopulation." @default.
• W2899615648 created "2018-11-16" @default.
• W2899615648 creator A5002050515 @default.
• W2899615648 creator A5011137037 @default.
• W2899615648 creator A5015232096 @default.
• W2899615648 creator A5028841026 @default.
• W2899615648 creator A5032081163 @default.
• W2899615648 creator A5053589015 @default.
• W2899615648 creator A5063413978 @default.
• W2899615648 creator A5066663298 @default.
• W2899615648 creator A5073088129 @default.
• W2899615648 creator A5085691097 @default.
• W2899615648 date "2018-11-08" @default.
• W2899615648 modified "2023-09-25" @default.
• W2899615648 title "Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients—Analysis of the Phase III AIO KRK-0207 Trial" @default.
• W2899615648 cites W1934094702 @default.
• W2899615648 cites W1942560962 @default.
• W2899615648 cites W2015132197 @default.
• W2899615648 cites W2031698214 @default.
• W2899615648 cites W2045766910 @default.
• W2899615648 cites W2053439872 @default.
• W2899615648 cites W2055443426 @default.
• W2899615648 cites W2085633477 @default.
• W2899615648 cites W2100490225 @default.
• W2899615648 cites W2110803737 @default.
• W2899615648 cites W2112570485 @default.
• W2899615648 cites W2129998117 @default.
• W2899615648 cites W2130921932 @default.
• W2899615648 cites W2130982817 @default.
• W2899615648 cites W2132962287 @default.
• W2899615648 cites W2134519717 @default.
• W2899615648 cites W2138970634 @default.
• W2899615648 cites W2153211112 @default.
• W2899615648 cites W2169434236 @default.
• W2899615648 cites W2273698479 @default.
• W2899615648 cites W2470575266 @default.
• W2899615648 cites W2509067245 @default.
• W2899615648 doi "https://doi.org/10.3389/fonc.2018.00474" @default.
• W2899615648 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6236022" @default.
• W2899615648 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30467535" @default.
• W2899615648 hasPublicationYear "2018" @default.
• W2899615648 type Work @default.
• W2899615648 sameAs 2899615648 @default.
• W2899615648 citedByCount "14" @default.
• W2899615648 countsByYear W28996156482019 @default.
• W2899615648 countsByYear W28996156482020 @default.
• W2899615648 countsByYear W28996156482021 @default.
• W2899615648 countsByYear W28996156482022 @default.
• W2899615648 countsByYear W28996156482023 @default.
• W2899615648 crossrefType "journal-article" @default.
• W2899615648 hasAuthorship W2899615648A5002050515 @default.
• W2899615648 hasAuthorship W2899615648A5011137037 @default.
• W2899615648 hasAuthorship W2899615648A5015232096 @default.
• W2899615648 hasAuthorship W2899615648A5028841026 @default.
• W2899615648 hasAuthorship W2899615648A5032081163 @default.
• W2899615648 hasAuthorship W2899615648A5053589015 @default.
• W2899615648 hasAuthorship W2899615648A5063413978 @default.
• W2899615648 hasAuthorship W2899615648A5066663298 @default.
• W2899615648 hasAuthorship W2899615648A5073088129 @default.
• W2899615648 hasAuthorship W2899615648A5085691097 @default.
• W2899615648 hasBestOaLocation W28996156481 @default.
• W2899615648 hasConcept C121608353 @default.
• W2899615648 hasConcept C126322002 @default.
• W2899615648 hasConcept C143998085 @default.
• W2899615648 hasConcept C2776694085 @default.
• W2899615648 hasConcept C2777802072 @default.
• W2899615648 hasConcept C2777968868 @default.
• W2899615648 hasConcept C2779438470 @default.
• W2899615648 hasConcept C2780806702 @default.
• W2899615648 hasConcept C2780962732 @default.
• W2899615648 hasConcept C502942594 @default.
• W2899615648 hasConcept C526805850 @default.
• W2899615648 hasConcept C71924100 @default.
• W2899615648 hasConceptScore W2899615648C121608353 @default.
• W2899615648 hasConceptScore W2899615648C126322002 @default.
• W2899615648 hasConceptScore W2899615648C143998085 @default.
• W2899615648 hasConceptScore W2899615648C2776694085 @default.
• W2899615648 hasConceptScore W2899615648C2777802072 @default.
• W2899615648 hasConceptScore W2899615648C2777968868 @default.
• W2899615648 hasConceptScore W2899615648C2779438470 @default.
• W2899615648 hasConceptScore W2899615648C2780806702 @default.
• W2899615648 hasConceptScore W2899615648C2780962732 @default.
• W2899615648 hasConceptScore W2899615648C502942594 @default.
• W2899615648 hasConceptScore W2899615648C526805850 @default.
• W2899615648 hasConceptScore W2899615648C71924100 @default.
• W2899615648 hasLocation W28996156481 @default.
• W2899615648 hasLocation W28996156482 @default.
• W2899615648 hasLocation W28996156483 @default.
• W2899615648 hasLocation W28996156484 @default.
• W2899615648 hasLocation W28996156485 @default.
• W2899615648 hasLocation W28996156486 @default.
• W2899615648 hasOpenAccess W2899615648 @default.
• W2899615648 hasPrimaryLocation W28996156481 @default.
• W2899615648 hasRelatedWork W1997133872 @default.
• W2899615648 hasRelatedWork W2050348440 @default.
• W2899615648 hasRelatedWork W2051540233 @default.
• W2899615648 hasRelatedWork W2058084084 @default.
• W2899615648 hasRelatedWork W2098707609 @default.
• W2899615648 hasRelatedWork W2145753255 @default.
• W2899615648 hasRelatedWork W2316610093 @default.

• next